First-in-Human Trial Launches for Novel NMDA Receptor Antagonist SP-101
Researchers at Shanghai Mental Health Center have initiated a first-in-human clinical trial of SP-101, a novel intravenous non-competitive NMDA receptor antagonist designed to potentially address neuropsychiatric conditions.
The phase 1, randomized, double-blind, placebo-controlled study (NCT07334249) will evaluate the safety, tolerability, and pharmacokinetics of SP-101 in 80 healthy adult volunteers through single and multiple ascending dose protocols.
Trial Design and Objectives
The trial features a 3:1 randomization ratio between SP-101 and placebo groups, with participants receiving intravenous infusions across escalating dose levels. Primary endpoints focus on treatment-emergent adverse events, with comprehensive pharmacokinetic assessments including peak plasma concentration, volume of distribution, and clearance parameters.
Key design elements include:
- 80 total participants
- Age range: 18-45 years
- Anticipated completion: December 2026
- Primary completion date: June 2026
Broader Context
NMDA receptor antagonists represent a promising therapeutic approach across multiple neurological and psychiatric indications. The current landscape includes over 25 companies developing molecules targeting this receptor, with ongoing investigations spanning major depressive disorder, Parkinson's disease, and schizophrenia.
Recent pipeline analyses suggest increasing scientific interest in NMDA receptor modulation, particularly for treatment-resistant psychiatric conditions. While ketamine and derivative compounds have dominated early research, novel molecules like SP-101 aim to provide more refined therapeutic profiles with potentially reduced side effect burdens.